PT2981624T - Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro - Google Patents

Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro

Info

Publication number
PT2981624T
PT2981624T PT147794036T PT14779403T PT2981624T PT 2981624 T PT2981624 T PT 2981624T PT 147794036 T PT147794036 T PT 147794036T PT 14779403 T PT14779403 T PT 14779403T PT 2981624 T PT2981624 T PT 2981624T
Authority
PT
Portugal
Prior art keywords
assessing
materials
methods
homologous recombination
recombination deficiency
Prior art date
Application number
PT147794036T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51659359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2981624(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Publication of PT2981624T publication Critical patent/PT2981624T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
PT147794036T 2013-04-05 2014-04-04 Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro PT2981624T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361809105P 2013-04-05 2013-04-05
US201361913762P 2013-12-09 2013-12-09

Publications (1)

Publication Number Publication Date
PT2981624T true PT2981624T (pt) 2020-03-23

Family

ID=51659359

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147794036T PT2981624T (pt) 2013-04-05 2014-04-04 Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro

Country Status (9)

Country Link
US (4) US20140363521A1 (https=)
EP (2) EP3693475A1 (https=)
JP (5) JP6625045B2 (https=)
AU (3) AU2014248007B2 (https=)
CA (1) CA2908745C (https=)
DK (1) DK2981624T3 (https=)
ES (1) ES2777228T3 (https=)
PT (1) PT2981624T (https=)
WO (1) WO2014165785A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
KR20190002733A (ko) 2010-12-30 2019-01-08 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
EP4563709A3 (en) 2011-06-17 2025-09-03 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
CN107267598B (zh) 2011-12-21 2022-03-25 美瑞德生物工程公司 用于评估杂合性丢失的方法与材料
WO2013130347A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
ES2658867T3 (es) 2012-06-07 2018-03-12 Institut Curie Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
DK2981624T3 (da) * 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
EP3080292B1 (en) 2013-12-09 2022-02-02 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EA201691682A1 (ru) 2014-02-21 2017-02-28 Эпик Сайенсиз, Инк. Способы анализирования редких циркулирующих в крови клеток
EP4234711B1 (en) 2014-08-15 2025-05-28 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
EP3227464B1 (en) * 2014-12-05 2022-04-20 Foundation Medicine, Inc. Multigene analysis of tumor samples
US20160160294A1 (en) * 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
GB2553736A (en) 2015-05-19 2018-03-14 S Sridhar T Method for identification of a deficient BRCA1 function
WO2017079139A1 (en) * 2015-11-03 2017-05-11 Epic Sciences, Inc. Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
WO2017106365A1 (en) * 2015-12-14 2017-06-22 Myriad Genetics, Inc. Methods for measuring mutation load
US20190025312A1 (en) * 2016-01-06 2019-01-24 Epic Sciences, Inc. Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
WO2017165270A1 (en) * 2016-03-21 2017-09-28 Myriad Genetics, Inc. Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer
WO2017178509A1 (en) 2016-04-12 2017-10-19 Xentech Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients
GB2555765A (en) 2016-05-01 2018-05-16 Genome Res Ltd Method of detecting a mutational signature in a sample
EP3452937B1 (en) 2016-05-01 2025-10-22 Genome Research Limited Method of characterising a dna sample
JP7224185B2 (ja) * 2016-05-01 2023-02-17 ゲノム・リサーチ・リミテッド Ｄｎａサンプルを特徴付ける方法
KR20230042136A (ko) 2016-06-29 2023-03-27 테사로, 인코포레이티드 난소암의 치료 방법
SG11202011696TA (en) 2018-06-11 2020-12-30 Foundation Medicine Inc Compositions and methods for evaluating genomic alterations
JPWO2020137076A1 (ja) * 2018-12-28 2021-11-11 国立大学法人 東京大学 Ｐａｒｐ阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法
AU2020221845A1 (en) 2019-02-12 2021-09-02 Tempus Ai, Inc. An integrated machine-learning framework to estimate homologous recombination deficiency
AU2020398913A1 (en) 2019-12-10 2022-06-16 Tempus Ai, Inc. Systems and methods for predicting homologous recombination deficiency status of a specimen
JP2023506084A (ja) * 2019-12-16 2023-02-14 アジレント・テクノロジーズ・インク ゲノム瘢痕アッセイ及び関連する方法
EP3945525A1 (en) 2020-07-27 2022-02-02 Sophia Genetics S.A. Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data
CN111883211B (zh) * 2020-08-07 2021-04-23 张哲� 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法
US11718869B2 (en) * 2020-08-12 2023-08-08 Zhenyue Biotechnology Jiangsu Co., Ltd. Method and kit for determining genome instability based on next generation sequencing (NGS)
CN112410423B (zh) * 2020-11-03 2021-08-13 南京世和基因生物技术股份有限公司 同源重组缺失的标志物、检测方法以及检测系统
JP7585015B2 (ja) 2020-12-04 2024-11-18 株式会社東芝 核酸構築物のセット、キット、検出方法及び薬剤効果予測方法
JP7696647B2 (ja) * 2021-01-10 2025-06-23 エーシーティー ジェノミックス （アイピー） リミテッド 相同組換え修復欠損を判定する方法及びそのキット
BE1029144B1 (fr) 2021-02-25 2022-09-20 Oncodna Méthode de caracterisation d'une tumeur à l'aide d'un séquençage ciblé
CN112820351A (zh) * 2021-03-01 2021-05-18 江苏医联生物科技有限公司 检测肿瘤患者的突变和hrd评分指导用药的方法
WO2022272310A1 (en) * 2021-06-25 2022-12-29 Foundation Medicine, Inc. System and method of classifying homologous repair deficiency
CN118369439A (zh) * 2021-12-08 2024-07-19 麦利亚德基因公司 用于评估乳腺癌亚型中同源重组缺陷的方法和材料
KR102523938B1 (ko) * 2022-02-04 2023-04-19 가톨릭대학교 산학협력단 상동 재조합 결핍증 예측 모델의 모델링 방법
WO2024083971A1 (en) 2022-10-19 2024-04-25 Vib Vzw Method of determining loss of heterozygosity status of a tumor
WO2025078404A1 (en) 2023-10-10 2025-04-17 Vib Vzw Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair
WO2025078387A1 (en) 2023-10-10 2025-04-17 Vib Vzw Method of detecting loss of heterozygosity status of a tumor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1432562A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
ES444380A1 (es) 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
DK0612248T3 (da) 1991-11-15 2003-12-08 Smithkline Beecham Corp Præparat, der indeholder cisplatin og topotecan som antitumormiddel
GB9806324D0 (en) 1998-03-24 1998-05-20 Pharmacia & Upjohn Spa Antitumour synergetic composition
MXPA03004832A (es) 2000-12-01 2004-05-04 Guilford Pharm Inc Compuestos y sus usos.
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
WO2005002508A2 (en) 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
WO2005004805A2 (en) 2003-07-02 2005-01-20 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
SI1660095T1 (sl) 2003-07-25 2010-05-31 Cancer Rec Tech Ltd Triciklični parp inhibitorji
CA2535584A1 (en) 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
DE602006018299D1 (de) 2005-06-30 2010-12-30 Bionumerik Pharmaceuticals Inc Platinanaloga mit monoazolligand
KR100925337B1 (ko) * 2009-05-25 2009-11-09 주식회사 마크로젠 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측
DK3327148T3 (da) * 2010-06-18 2021-04-12 Myriad Genetics Inc Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle
ES2704303T3 (es) * 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
WO2013130347A1 (en) * 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
DK2981624T3 (da) * 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling

Also Published As

Publication number Publication date
JP2023012488A (ja) 2023-01-25
AU2022211880B2 (en) 2025-05-29
US20180030544A1 (en) 2018-02-01
JP2021036903A (ja) 2021-03-11
CA2908745C (en) 2023-03-14
AU2020204028A1 (en) 2020-07-09
DK2981624T3 (da) 2020-03-02
EP2981624B1 (en) 2019-12-18
WO2014165785A2 (en) 2014-10-09
JP7641938B2 (ja) 2025-03-07
JP2025090619A (ja) 2025-06-17
AU2022211880A1 (en) 2022-09-01
JP7522643B2 (ja) 2024-07-25
JP2019165731A (ja) 2019-10-03
JP2016523511A (ja) 2016-08-12
US20140363521A1 (en) 2014-12-11
US20250223655A1 (en) 2025-07-10
JP7522539B2 (ja) 2024-07-25
AU2020204028B2 (en) 2022-08-18
CA2908745A1 (en) 2014-10-09
NZ712663A (en) 2021-07-30
US20210310079A1 (en) 2021-10-07
EP3693475A1 (en) 2020-08-12
AU2014248007A1 (en) 2015-10-15
EP2981624A4 (en) 2016-11-30
ES2777228T3 (es) 2020-08-04
JP6625045B2 (ja) 2019-12-25
AU2014248007B2 (en) 2020-03-26
EP2981624A2 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
PT2981624T (pt) Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro
PT3180447T (pt) Métodos e materiais para avaliar a deficiência de recombinação homóloga
IL245573A0 (en) cell
SI2976013T1 (sl) Postopki za ocenjevanje eritema
ZA201505705B (en) Phi-4 polypeptides and methods for their use
GB201413353D0 (en) Compositions and methods
GB201308072D0 (en) Compositions and methods
GB201201100D0 (en) Polypeptides and methods
GB201305813D0 (en) Compositions and methods
IL243361B (en) Radioactively labeled material
GB201310031D0 (en) Cell
GB201308066D0 (en) Mattress materials
SG10201708046YA (en) Nanoprobe-Based Genetic Testing
GB201312332D0 (en) Cell locations
GB2515832B (en) Receptacle
GB201317355D0 (en) Mutation Analysis
GB201310558D0 (en) Genetic test
IL240033B (en) A method to assess the aging of a cell
GB2520506B (en) Partial Scan Cell
HUE035872T2 (hu) Raktár és raktározási eljárás
GB201314622D0 (en) Material inspection
GB201315372D0 (en) Barbecue/cook-station
GB201210303D0 (en) Polypeptides and methods
GB201320801D0 (en) Particle Characterization
GB201320573D0 (en) T Cell